Last reviewed · How we verify

NCT02445703

Phase IV Immunogenicity and Safety Study of Different Immunization Schedules of Inactivated Hepatitis A Vaccine (HAV) and/ or Combined Hepatitis A and Hepatitis B Vaccine (HABV) in Healthy Chinese Infants

Completed Phase 4 Last updated 26 July 2021
What this trial tests

Phase 4 trial testing Inactivated Hepatitis A vaccine (HAV) in Hepatitis A in 301 participants. Completed in 1 June 2016.

Timeline
1 May 2014
Primary endpoint
1 January 2015
1 June 2016

Quick facts

Lead sponsorSinovac Biotech Co., Ltd
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment301
Start date1 May 2014
Primary completion1 January 2015
Estimated completion1 June 2016
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sinovac Biotech Co., Ltd — full company profile →

Who can join

Adults 18 Months to 24 Months, any sex, with Hepatitis A or Hepatitis B. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to compare the immunogenicity and safety of three different immunization schedules of inactivated hepatitis A vaccine (HAV) and/ or combined hepatitis A and B vaccine (HABV) in healthy Chinese infants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hepatitis A

Currently open trials in the same condition.

Other Sinovac Biotech Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02445703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing